-
2 months ago | 
modernretina.com | John W. Kitchens |Richard M. Gale |Michael Stewart
January 31, 2025By Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases. Video content above is prompted by the following: What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases? Related Content Related Content
-
Jan 10, 2025 | 
modernretina.com | John W. Kitchens |Richard M. Gale |Michael Stewart
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
-
Jan 9, 2025 | 
eyetube.net | Adrienne W. Scott |Steven Sanislo |John W. Kitchens |Judy E. Kim
05.03.23 Treating GA In Your Clinic Allen C. Ho, MD; Robert L. Avery, MD; Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD 02.24.22 Anti-VEGF, A Biography: Part 3 John D. Pitcher III, MD; Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD 02.17.22 Anti-VEGF, A Biography: Part 2 John D.
-
Jan 9, 2025 | 
eyetube.net | Adrienne W. Scott |Steven Sanislo |John W. Kitchens |Judy E. Kim
05.03.23 Treating GA In Your Clinic Allen C. Ho, MD; Robert L. Avery, MD; Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD 02.24.22 Anti-VEGF, A Biography: Part 3 John D. Pitcher III, MD; Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD 02.17.22 Anti-VEGF, A Biography: Part 2 John D.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Anti-VEGF for RVO: The Gold Standard John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 | 
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 4Anti-VEGF for RVO: The Gold Standard Published on: October 16, 2024John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 | 
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 3Faricimab for DME: Durability and Patient Outcomes Published on: October 16, 2024Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for DME: Durability and Patient Outcomes Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for nAMD: Key Trial Highlights and Case Example Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Overview of Real-World Outcomes for nAMD, DME, and RVO Patients Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.
